European Patent Office: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
DrugPatentWatch® Estimated Loss of Exclusivity Dates in European Patent Office
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: European Patent Office: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| PANCREAZE | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| ZENPEP | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| EMBEDA | morphine sulfate; naltrexone hydrochloride | 2026-06-19 |
| EMBEDA | morphine sulfate; naltrexone hydrochloride | 2027-06-19 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: European Patent Office: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: European Patent Office Patent 2,034,975
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,484,346
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: European Patent Office Patent 2,526,932
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,719,378
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can RYTARY (carbidopa; levodopa) generic drug versions launch?
Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 28, 2027
Generic Entry Controlled by: European Patent Office Patent 2,234,963
RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-five patent family members in twelve countries. There has been litigation on patents covering RYTARY
See drug price trends for RYTARY.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this API. Thirty-seven suppliers are listed for this generic product. Additional details are available on the carbidopa; levodopa profile page.
When can BEVYXXA (betrixaban) generic drug versions launch?
Generic name: betrixaban
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,760
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 25, 2026
Generic Entry Controlled by: European Patent Office Patent 2,068,842
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 1,940,364
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: European Patent Office Patent 2,064,189
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: European Patent Office Patent 2,824,098
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can NINLARO (ixazomib citrate) generic drug versions launch?
Generic name: ixazomib citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,178,888
NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.
This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO
See drug price trends for NINLARO.
The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,322,516
OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.
This drug has sixty-four patent family members in forty-one countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch?
Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 12, 2027
Generic Entry Controlled by: European Patent Office Patent 2,207,526
PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering PREPOPIK
See drug price trends for PREPOPIK.
The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: European Patent Office Patent 2,046,318
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,450,035
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: European Patent Office Patent 2,046,318
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,450,035
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can VIZAMYL (flutemetamol f-18) generic drug versions launch?
Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 30, 2027
Generic Entry Controlled by: European Patent Office Patent 2,182,988
VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.
This drug has twenty-three patent family members in twenty countries.
See drug price trends for VIZAMYL.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this generic product. Additional details are available on the flutemetamol f-18 profile page.
When can INTRAROSA (prasterone) generic drug versions launch?
Generic name: prasterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: European Patent Office Patent 2,185,157
This drug has fifty-nine patent family members in thirty-two countries.
See drug price trends for INTRAROSA.
The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.
When can SALONPAS (menthol; methyl salicylate) generic drug versions launch?
Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,047,845
SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.
This drug has twenty patent family members in sixteen countries.
The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,473
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can XIIDRA (lifitegrast) generic drug versions launch?
Generic name: lifitegrast
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,209,371
This drug has one hundred and thirty-five patent family members in twenty-four countries. There has been litigation on patents covering XIIDRA
See drug price trends for XIIDRA.
The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this generic product. Additional details are available on the lifitegrast profile page.
When can XIIDRA (lifitegrast) generic drug versions launch?
Generic name: lifitegrast
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 19, 2027
Generic Entry Controlled by: European Patent Office Patent 3,167,886
This drug has one hundred and thirty-five patent family members in twenty-four countries. There has been litigation on patents covering XIIDRA
See drug price trends for XIIDRA.
The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this generic product. Additional details are available on the lifitegrast profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: European Patent Office Patent 2,363,392
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,978,015
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch?
Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,016,940
TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.
This drug has thirteen patent family members in eleven countries.
See drug price trends for TRIFERIC.
The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,407,475
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can RASUVO (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,046,332
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,018,160
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch?
Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering TUZISTRA XR
See drug price trends for TUZISTRA XR.
The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this API. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.
When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,102,224
This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR
See drug price trends for INVOKAMET XR.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can MYRBETRIQ (mirabegron) generic drug versions launch?
Generic name: mirabegron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2027
Generic Entry Controlled by: European Patent Office Patent 2,216,021
MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has fifty-three patent family members in twenty-five countries. There has been litigation on patents covering MYRBETRIQ
See drug price trends for MYRBETRIQ.
The generic ingredient in MYRBETRIQ is mirabegron. There are nineteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the mirabegron profile page.
When can ORENITRAM (treprostinil diolamine) generic drug versions launch?
Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2026
Generic Entry Controlled by: European Patent Office Patent 2,010,189
ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM
See drug price trends for ORENITRAM.
The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.
When can ORENITRAM (treprostinil diolamine) generic drug versions launch?
Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2026
Generic Entry Controlled by: European Patent Office Patent 2,368,556
ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM
See drug price trends for ORENITRAM.
The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: European Patent Office Patent 2,073,795
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: European Patent Office Patent 2,200,593
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: European Patent Office Patent 2,692,341
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can APTIOM (eslicarbazepine acetate) generic drug versions launch?
Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,319,836
This drug has ninety-three patent family members in twenty-six countries. There has been litigation on patents covering APTIOM
See drug price trends for APTIOM.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.
When can BELSOMRA (suvorexant) generic drug versions launch?
Generic name: suvorexant
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: European Patent Office Patent 2,089,382
This drug has seventy-five patent family members in thirty-six countries.
See drug price trends for BELSOMRA.
The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.
When can BELSOMRA (suvorexant) generic drug versions launch?
Generic name: suvorexant
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 30, 2027
Generic Entry Controlled by: European Patent Office Patent 2,392,572
This drug has seventy-five patent family members in thirty-six countries.
See drug price trends for BELSOMRA.
The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.
When can BRILINTA (ticagrelor) generic drug versions launch?
Generic name: ticagrelor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,056,832
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,183,244
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,102,224
This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET
See drug price trends for INVOKAMET.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 2,173,752
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 2,740,731
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,070,090
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,495,369
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,185,138
This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO
See drug price trends for KAZANO.
The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch?
Generic name: ambrisentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,777
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,124,901
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can OPSUMIT (macitentan) generic drug versions launch?
Generic name: macitentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: European Patent Office Patent 2,059,246
OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT
See drug price trends for OPSUMIT.
The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,107,905
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 26, 2027
Generic Entry Controlled by: European Patent Office Patent 1,989,182
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,152,237
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can SAVAYSA (edoxaban tosylate) generic drug versions launch?
Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: European Patent Office Patent 2,140,867
This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA
See drug price trends for SAVAYSA.
The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: European Patent Office Patent 2,086,940
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?
Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2026
Generic Entry Controlled by: European Patent Office Patent 2,034,968
This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT
See drug price trends for TEKTURNA HCT.
The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: European Patent Office Patent 2,023,902
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,277,509
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,283,819
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: European Patent Office Patent 2,044,043
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: European Patent Office Patent 2,439,201
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 22, 2027
Generic Entry Controlled by: European Patent Office Patent 2,136,793
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,029,524
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: European Patent Office Patent 2,474,521
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,101,740
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: European Patent Office Patent 2,217,610
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: European Patent Office Patent 3,150,617
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,137,143
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: European Patent Office Patent 2,081,921
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can INQOVI (cedazuridine; decitabine) generic drug versions launch?
Generic name: cedazuridine; decitabine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: European Patent Office Patent 2,207,786
INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.
This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI
See drug price trends for INQOVI.
The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.